READ MORE ACCUTANE IBD LEGAL NEWS
Lead researcher Marius Rademaker and his colleagues reviewed the cases of 1,743 patients who were given isotretinoin to treat acne. This review revealed that patients who took less than 0.25 mg of the medication were far less likely to experience adverse side effects.
Specifically, the researchers discovered that 47 percent of those taking the lower dose of isotretinoin experienced cheilitis, a condition that inflames the lips, compared to 96 percent of those on higher dosages. Similar results were found for eczema and tiredness as well.
Introduced to the market in the 1980s, Accutane was recently pulled in part because of its harmful side effects, which include ulcerative colitis and inflammatory bowel disease.